Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Phase 2

Recruiting

Conditions: Thalassemia
Sickle Cell Disease
Thalassemia, Beta

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Biological: Rabbit ATG
Drug: Dexamethasone
Drug: Bortezomib
Drug: Rituximab

First Posted Date: 2023-02-21

Last Posted Date: 2024-05-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT05736419

Locations: 🇺🇸
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States

and more 3 locations

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Large B Cell Lymphoma

Interventions: Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide
Genetic: ALLO-501A

First Posted Date: 2023-02-06

Last Posted Date: 2024-05-31

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 70

Registration Number: NCT05714345

Locations: 🇧🇪
Universitair Ziekenhuis Brussel, Brussel, Belgium
🇺🇸
University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukaemia

Interventions: Drug: SAR445419
Drug: fludarabine
Drug: cytarabine

First Posted Date: 2023-02-03

Last Posted Date: 2024-04-12

Lead Sponsor: Sanofi

Target Recruit Count: 7

Registration Number: NCT05712278

Locations: 🇺🇸
~MD Anderson Cancer Center Site Number : 8400002, Houston, Texas, United States
🇺🇸
University of Nebraska Medical Center Site Number : 8400003, Omaha, Nebraska, United States
🇺🇸
Albert Einstein College of Medicine Site Number : 8400001, Bronx, New York, United States

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

Phase 1

Recruiting

Conditions: B Acute Lymphoblastic Leukemia

Interventions: Drug: Autologous Anti-CD19 CAR-expressing T Lymphocytes
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Leukapheresis
Other: Questionnaire Administration

First Posted Date: 2023-01-31

Last Posted Date: 2024-06-18

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 21

Registration Number: NCT05707273

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Phase 1

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia Refractory
B-cell Lymphoma Refractory
B-cell Lymphoma Recurrent
Acute Lymphoblastic Leukemia, in Relapse
Chronic Lymphocytic Leukemia Recurrent
Chronic Lymphocytic Leukemia Refractory

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0

First Posted Date: 2023-01-31

Last Posted Date: 2023-01-31

Lead Sponsor: Hospital Israelita Albert Einstein

Target Recruit Count: 30

Registration Number: NCT05705570

Locations: 🇧🇷
Hospital Israelita Albert Einstein, São Paulo, Brazil

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Phase 1

Recruiting

Conditions: Advanced Renal Cell Carcinoma
Advanced Mesothelioma
Advanced Osteosarcoma

Interventions: Drug: CAR.70/IL15-transduced CB-derived NK cells
Drug: Fludarabine phosphate
Drug: Cyclophosphamide

First Posted Date: 2023-01-30

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT05703854

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Biological: Pan-T booster co-expressing MSLN CAR T cell
Drug: Albumin-bound paclitaxel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-01-23

Last Posted Date: 2024-05-10

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 15

Registration Number: NCT05693844

Locations: 🇨🇳
Kaichao Feng, Beijing, Beijing, China

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Phase 1

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma
Triple Negative Breast Cancer Malignancies
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: PRGN-3007

First Posted Date: 2023-01-23

Last Posted Date: 2024-12-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT05694364

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Phase 1

Recruiting

Conditions: Non Small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Recurrent Non Small Cell Lung Cancer

Interventions: Biological: Tumor-infiltrating Lymphocytes (TIL)
Drug: Nivolumab
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Tumor-infiltrating Lymphocyte Therapy
Drug: Interleukin-2 (IL2)

First Posted Date: 2023-01-12

Last Posted Date: 2024-12-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT05681780

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Phase 1

Recruiting

Conditions: HER2 Positive Advanced Solid Tumors

Interventions: Biological: HypoSti.CAR-HER2 T cells
Drug: Albumin-bound paclitaxel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-01-12

Last Posted Date: 2023-12-12

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 30

Registration Number: NCT05681650

Locations: 🇨🇳
Kaichao Feng, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy